Quince Therapeutics, Inc.

Quince Therapeutics develops medicines for rare genetic diseases. The company's main focus is a drug candidate called eDSP for ataxia-telangiectasia, a rare inherited disorder that damages the nervous system and immune system. Quince uses a technology platform called AIDE that takes a patient's own red blood cells and loads them with medicine using a specialized automated machine. The company was previously called Cortexyme before changing its name in 2022.